Targets › F11
6 programs from 5 companies in 23 trials: 14 Phase 3, 5 Phase 1, 4 Phase 2; Cardiovascular, Genitourinary, Other; next expected readout Dec 2026.
Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. (UniProt, P03951)
Open in Phaseline: the race on F11, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Johnson & Johnson (Janssen) | Milvexian Coagulation factor XI inhibitor | F11 | Phase 3 | Ischemic Stroke; Ischemic Attack, Transient; Atrial Fibrillation | Dec 2026 |
| Regeneron Pharmaceuticals | REGN7508 Factor XI inhibitor | F11 | Phase 3 | Venous Thromboembolism (VTE); Symptomatic Venous Thromboembolism (VTE); Atrial Fibrillation (AF); Peripheral Artery Disease (PAD) … | Feb 2027 |
| Regeneron Pharmaceuticals | REGN9933 Factor XI inhibitor | F11 | Phase 3 | Atrial Fibrillation (AF); Venous Thromboembolism (VTE); Peripheral Artery Disease (PAD); End-Stage Kidney Disease (ESKD) | Feb 2027 |
| Anthos Therapeutics | Abelacimab (MAA868) Coagulation factor XI inhibitor | F11 | Phase 3 | Atrial Fibrillation (AF) | Dec 2027 |
| Suzhou Alphamab | KN060 Factor XI inhibitor | F11 | Phase 2 | Knee Arthroplasty, Total; Hypertension; End-Stage Renal Disease Requiring Haemodialysis | Dec 2026 |
| Sirnaomics | FXI-GalNAc-siRNA Factor XI silencing RNA (GalNAc-conjugated siRNA) | F11 | Phase 1 | FXI | May 2027 |
Atrial Fibrillation (AF) (7) Venous Thromboembolism (VTE) (4) Peripheral Artery Disease (PAD) (2) End-Stage Kidney Disease (ESKD) (2) Symptomatic Venous Thromboembolism (VTE) (1) Cancer-Associated Thrombosis (CAT) (1) Knee Arthroplasty, Total (1) Hypertension (1) End-Stage Renal Disease Requiring Haemodialysis (1) Ischemic Stroke; Ischemic Attack, Transient (1) Atrial Fibrillation (1) FXI (1)
mixed (3), small molecule (2), other (1)
Regeneron Pharmaceuticals (2) Suzhou Alphamab (1) Anthos Therapeutics (1) Johnson & Johnson (Janssen) (1) Sirnaomics (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.